.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Chinese Patent Office
UBS
Fuji
Chubb
Colorcon
Federal Trade Commission
Baxter
Medtronic
US Army

Generated: September 20, 2017

DrugPatentWatch Database Preview

Dronedarone hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for dronedarone hydrochloride and what is the scope of dronedarone hydrochloride patent protection?

Dronedarone hydrochloride
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Dronedarone hydrochloride has one hundred and forty-four patent family members in fifty-seven countries.

There are nineteen drug master file entries for dronedarone hydrochloride. Four suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: dronedarone hydrochloride

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: see list19
Suppliers / Packagers: see list4
Bulk Api Vendors: see list58
Clinical Trials: see list2,300
Patent Applications: see list139
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:dronedarone hydrochloride at DailyMed

Pharmacology for Ingredient: dronedarone hydrochloride

Tentative approvals for DRONEDARONE HYDROCHLORIDE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe400MGTABLET;ORAL
► Subscribe► Subscribe400MGTABLET;ORAL
► Subscribe► Subscribe400MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: dronedarone hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
MULTAQ
dronedarone hydrochloride
TABLET;ORAL022425-001Jul 1, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: dronedarone hydrochloride

Country Document Number Estimated Expiration
BrazilPI0910631► Subscribe
Peru17772009► Subscribe
Uruguay31767► Subscribe
European Patent Office1007030► Subscribe
Morocco32354► Subscribe
China1267217► Subscribe
World Intellectual Property Organization (WIPO)2009144551► Subscribe
Germany69823360► Subscribe
Hungary912610► Subscribe
France2665444► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DRONEDARONE HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
22/2010Austria► SubscribePRODUCT NAME: DRONEDARON ODER PHARMAZEUTISCH ANNEHMBARE SALZE HIEVON
1007030/01Switzerland► SubscribePRODUCT NAME: DRONEDARONUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 59292 16.09.2009
4Finland► Subscribe
2010003,C1007030Lithuania► SubscribePRODUCT NAME: DRONEDARONUM; REGISTRATION NO/DATE: EU/1/09/591/001, 2009 11 26 EU/1/09/591/002, 2009 11 26 EU/1/09/591/003, 2009 11 26 EU/1/09/591/004 20091126
00446Netherlands► SubscribePRODUCT NAME: DRONEDARON, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/09/591/001-004 20091126
2010 00018Denmark► Subscribe
673Luxembourg► Subscribe91673, EXPIRES: 20230619
C008/2010Ireland► SubscribeSPC008/2010: 20101015, EXPIRES: 20230616
10008Ireland► SubscribeTHE CORRECT SPC EXTENSION DATE IS 20230618 (NOT 20230616); PRODUCT NAME: DRONEDARONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/09/591/001-004 20091126
2010003Lithuania► SubscribePRODUCT NAME: DRONEDARONUM; REGISTRATION NO/DATE: EU/1/09/591/001, 2009 11 26 EU/1/09/591/002, 2009 11 26 EU/1/09/591/003, 2009 11 26 EU/1/09/591/004 20091126
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Dow
Cerilliant
McKinsey
Healthtrust
Merck
US Department of Justice
Citi
Fuji
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot